Literature DB >> 8859177

Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis.

C Hirota1, M Iida, K Aoyagi, T Matsumoto, S Tada, T Yao, M Fujishima.   

Abstract

BACKGROUND: Oral sulindac is known to reduce polyps in patients with familial adenomatous polyposis (FAP). The authors speculated that rectal administration of indomethacin would be effective therapy for adenomas in the rectal remnant of FAP.
METHODS: Eight patients with FAP who had been treated by total colectomy with ileorectal anastomosis were administered an indomethacin suppository (50 mg) once or twice daily during a period of 4 or 8 weeks. The number of polyps at the same site within the rectum was counted under proctoscopy prior to, at the end of, and after the treatment. In four patients, proliferative activity of the rectal mucosa was assessed by immunohistochemical staining for MIB-1.
RESULTS: In six of the eight patients who initially had ten or more polyps, the number of polyps decreased to fewer than five, whereas such a decrease could not be observed in the remaining two patients. In the six patients, the number of polyps increased after indomethacin was discontinued. The proliferative activity of the rectal mucosa was higher at the end of treatment than it was prior to indomethacin administration.
CONCLUSIONS: Indomethacin suppositories may be effective in the management of rectal adenomatosis in patients with FAP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859177

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Chemoprevention in familial adenomatous polyposis.

Authors:  Brian Kim; Francis M Giardiello
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

2.  Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development.

Authors:  Y Shoji; M Takahashi; T Kitamura; K Watanabe; T Kawamori; T Maruyama; Y Sugimoto; M Negishi; S Narumiya; T Sugimura; K Wakabayashi
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

3.  Chemoprevention in patients with genetic risk of colorectal cancers.

Authors:  Christina M Laukaitis; Steven H Erdman; Eugene W Gerner
Journal:  Colorectal Cancer       Date:  2012

4.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

5.  Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.

Authors:  E M J Boon; J J Keller; T A M Wormhoudt; F M Giardiello; G J A Offerhaus; R van der Neut; S T Pals
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.